Collectively, all of these things will be to our benefit & as usual this board has considered all the angles based on what has been shared to date. As I skimmed, there were dozens of great posts.
Landed on this one as I just revisited cc at 1min 5sec. HIV BLA is what is most used against us & the spark that lighted the fire.
If company were to pursue HIV approval above everything else, it would not be all bad. 350 combo would be a little more bad. 13d has suggested that this path would require a reverse split & possibly result in a quick buck for some & a nice profit for investors in at .30 or so. At $1.00 or more it was hardly worth the effort. Above $3.00 & you just got yours handed to you, imho.
Imho a reverse split is not only agenda driven, but a backwards agenda.
So yes HIV as 1 of 30 will reap huge rewards over time. But just right now, HIV is not the "biotech Prom Queen". Her name is "covid 19".
IMHO, pps is suppressed by warrants, which do represent revenues. IMHO, when revenue from sale of product outweighs revenue from warrants, pps will skyrocket.
Imo, at 1min 5sec into cc NP stated that given current contracts & inventory, should Brazil trials prove to be successful & available inventory was sold it would be kind of stupid to argue about "my favorite vehicle".
Furthermore, it seems that the company may be pursuing more manufacturing. Love the whole Samsung thing, but no way can they supply enough. They have been instrumental in getting us to this point & will profit handsomely on what they are able to deliver(a fraction).